Chronic hepatitis B (CHB), caused by infection with hepatitis B virus (HBV), affects approximately 296 million people worldwide and remains a leading cause of cirrhosis and hepatocellular carcinoma (HCC). The pharmacological goal of CHB treatment is sustained suppression of HBV deoxyribonucleic acid (HBV DNA) to undetectable levels, which halts necroinflammation, reduces fibrosis progression, and lowers HCC risk. Two mechanistic approaches are available: nucleos(t)ide analogues (NAs), which suppress viral replication indefinitely as long as therapy continues, and pegylated interferon-alpha (PegIFN), which offers finite treatment duration with the possibility of durable off-therapy response.
The three preferred first-line NAs for CHB are tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF), and entecavir (ETV). All three are potent inhibitors of the HBV reverse transcriptase, the enzyme responsible for converting pregenomic RNA (ribonucleic acid) into HBV DNA during viral replication. NAs do not eliminate the covalently closed circular DNA (cccDNA) reservoir in hepatocyte nuclei, which is why treatment is generally lifelong in the absence of hepatitis B surface antigen (HBsAg) loss. TAF and TDF are prodrugs of tenofovir, a nucleotide analogue of adenosine monophosphate that competitively inhibits HBV reverse transcriptase and terminates chain elongation after incorporation into nascent viral DNA.1 TAF delivers tenofovir to hepatocytes more efficiently than TDF, achieving equivalent antiviral efficacy at a dose approximately ten times lower (25 mg vs. 300 mg daily), with substantially less systemic tenofovir exposure. This difference has clinical relevance: TDF carries dose-dependent risks of renal tubular toxicity (proximal tubular dysfunction, Fanconi syndrome) and reduced bone mineral density, while TAF has a substantially improved renal and bone safety profile. TAF is preferred over TDF in patients with renal impairment (estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73m²), low bone mineral density, or risk factors for either.
Entecavir (ETV) is a guanosine analogue that inhibits HBV reverse transcriptase at three steps: priming, reverse transcription of the negative strand, and synthesis of the positive strand of HBV DNA. ETV is highly potent and has an excellent resistance profile in treatment-naive patients, with resistance detected in less than 1.2% of patients after five years of treatment in clinical trials.2 However, ETV has a critical pharmacological limitation in lamivudine-experienced patients: the lamivudine resistance mutations (M204V and M204I) substantially reduce ETV efficacy, with resistance emerging in approximately 50% of lamivudine-resistant patients treated with ETV over five years. This cross-resistance pattern means ETV should not be used as rescue therapy for lamivudine-resistant HBV; TDF or TAF are the appropriate choices in that setting. All three preferred NAs have minimal drug interaction profiles because they are not metabolized by cytochrome P450 enzymes.
The principal treatment endpoint for NAs is undetectable HBV DNA on a sensitive polymerase chain reaction (PCR) assay, typically defined as below 20 IU (international units)/mL. Secondary endpoints include normalization of alanine aminotransferase (ALT), hepatitis B e antigen (HBeAg) seroconversion (loss of HBeAg and development of anti-HBe antibody), and ultimately HBsAg loss with seroconversion to anti-HBs. HBsAg loss, which reflects functional cure and elimination of cccDNA transcription activity, occurs in only 1–3% of NA-treated patients per year and remains an aspirational rather than routinely achievable endpoint with current NAs.3 HBeAg seroconversion is a meaningful intermediate endpoint in HBeAg-positive CHB: after durable seroconversion, treatment discontinuation can be considered in non-cirrhotic patients, though reactivation remains a risk requiring monitoring. In HBeAg-negative CHB, virological relapse after NA discontinuation is nearly universal, making indefinite treatment the standard for most patients.
Pegylated interferon-alpha (PegIFN) has both antiviral and immunomodulatory activities: it induces interferon-stimulated genes that inhibit viral replication and enhances innate and adaptive immune responses against HBV-infected hepatocytes. PegIFN-alpha-2a at 180 mcg subcutaneously weekly for 48 weeks is the standard finite treatment regimen. Its advantages over NAs are the defined treatment duration (48 weeks vs. indefinite), higher rates of HBeAg seroconversion and HBsAg decline, and absence of drug resistance. Its disadvantages are substantial: a difficult adverse effect profile including flu-like symptoms, fatigue, bone marrow suppression, depression, autoimmune exacerbations, and thyroid dysfunction; and strict contraindications including decompensated cirrhosis, autoimmune hepatitis, uncontrolled psychiatric disease, and cytopenias. On-treatment predictors of response include quantitative HBsAg decline and HBV genotype (genotypes A and B respond better than C and D).4 PegIFN is not recommended in cirrhotic patients due to the risk of precipitating hepatic decompensation.
HBV reactivation – abrupt increase in HBV DNA in a patient with resolved or inactive CHB – can occur when immunosuppressive therapy disrupts the immune surveillance that controls HBV. High-risk scenarios include anti-CD20 therapy (rituximab), hematopoietic stem cell transplant, high-dose corticosteroids, and checkpoint inhibitor therapy. Reactivation can cause acute liver failure and death. All patients scheduled for immunosuppressive therapy must be screened for HBsAg and anti-HBc (hepatitis B core antibody) before treatment. HBsAg-positive patients require prophylactic NA therapy initiated before and continued after immunosuppression. Anti-HBc-positive/HBsAg-negative patients (resolved infection) require at minimum close monitoring, and prophylactic treatment for high-risk regimens. TAF or ETV are preferred for prophylaxis given their potency and resistance profiles.
TAF 25 mg daily: Preferred in renal impairment, low bone mineral density, or elderly patients. Equal antiviral efficacy to TDF with improved safety profile. Use with caution when eGFR below 15 mL/min/1.73m² (limited data).
TDF 300 mg daily: Equivalent antiviral efficacy to TAF; preferred in pregnancy (more safety data) and where cost is a constraint (generic available). Monitor renal function and bone density in long-term use.
ETV 0.5 mg daily (NA-naive); 1 mg daily (lamivudine-experienced): Excellent resistance barrier in NA-naive patients. Avoid as monotherapy in lamivudine-resistant HBV. Dose-reduce in renal impairment.
All three agents: Avoid abrupt discontinuation in cirrhotic patients – risk of severe hepatitis flare from viral rebound. Taper with close HBV DNA and ALT monitoring if discontinuation is planned.
The pharmacological treatment of chronic hepatitis C virus (HCV) infection has been transformed by a new mechanistic class, DAA (direct-acting antiviral) agents, targeting specific nonstructural proteins essential for HCV replication. Current pan-genotypic DAA regimens achieve sustained virologic response at 12 weeks (SVR12 (undetectable HCV RNA (ribonucleic acid) at 12 weeks after completing treatment – the accepted definition of virological cure)) in over 95% of treatment-naive patients across all HCV genotypes, including cirrhotic patients, with 8–12 week oral regimens and minimal adverse effects. This represents a transformation from the era of pegylated interferon and ribavirin (RBV), where response rates were 40–80% genotype-dependent and toxicity was substantial.
DAAs target three viral proteins: the NS5B (nonstructural protein 5B) RNA-dependent RNA polymerase, the NS5A (nonstructural protein 5A) protein (a multifunctional replication complex scaffold), and the NS3/4A (nonstructural protein 3/4A) serine protease. Sofosbuvir (SOF) is a uridine nucleotide analogue prodrug that inhibits the HCV NS5B polymerase. After intracellular conversion to its active triphosphate form, it acts as a chain terminator, incorporating into nascent HCV RNA and halting elongation. Sofosbuvir has an exceptionally high barrier to clinical resistance; in phase 3 trials virological failure attributable to resistance was rare, reflecting the high fitness cost of the S282T (serine-to-threonine substitution at position 282 of NS5B) mutation, making sofosbuvir one of the most durable DAA components.5 It is eliminated renally as an inactive nucleotide metabolite (GS-331007), which accumulates significantly in severe renal impairment: sofosbuvir-containing regimens require dose adjustment or alternative selection when eGFR (estimated glomerular filtration rate) falls below 30 mL/min/1.73m².
NS5A inhibitors – ledipasvir, velpatasvir, pibrentasvir, and elbasvir – block the NS5A (nonstructural protein 5A) protein, which is essential for viral replication complex assembly and RNA replication, though its precise enzymatic function is incompletely characterized. NS5A inhibitors are highly potent and active across genotypes, particularly pibrentasvir, which has pan-genotypic activity including against genotype 3, historically the most treatment-resistant. The barrier to resistance with NS5A inhibitors alone is lower than with NS5B inhibitors, which is why they are always used in combination with at least one agent from another class. NS3/4A protease inhibitors – glecaprevir, grazoprevir, and voxilaprevir – block the NS3/4A (nonstructural protein 3/4A serine protease), which is required for processing the HCV polyprotein into functional nonstructural proteins. NS3/4A inhibitors have important drug interaction considerations: they are substrates and inhibitors of P-glycoprotein and CYP3A4 (cytochrome P450 3A4), with significant interactions with strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin) which reduce DAA levels to subtherapeutic concentrations and are absolute contraindications to concurrent use.6
The two current pan-genotypic first-line regimens are sofosbuvir/velpatasvir (SOF/VEL, Epclusa) and glecaprevir/pibrentasvir (GLE/PIB, Mavyret). SOF/VEL combines NS5B and NS5A inhibition and is administered as one tablet daily for 12 weeks in treatment-naive non-cirrhotic patients and 12 weeks in compensated cirrhosis. GLE/PIB combines NS3/4A and NS5A inhibition without an NS5B component; it is administered as three tablets daily for 8 weeks in treatment-naive non-cirrhotic patients across all genotypes, or 12 weeks in compensated cirrhosis. GLE/PIB has a renal advantage: unlike sofosbuvir-containing regimens, it does not require dose adjustment in renal impairment and is the preferred regimen for patients with chronic kidney disease (CKD) including those on dialysis.14 Sofosbuvir/velpatasvir/voxilaprevir (Vosevi) is a three-class pan-genotypic regimen reserved for treatment-experienced patients or genotype 3 with baseline NS5A resistance-associated substitutions.7
SVR12 represents virological cure: patients who achieve SVR12 do not relapse virologically and are considered cured of HCV infection in the vast majority of cases. Long-term follow-up studies demonstrate sustained HCV RNA negativity, regression of liver fibrosis (including partial reversal of cirrhosis in some patients), significant reduction in HCC (hepatocellular carcinoma) incidence (though not elimination in cirrhotic patients), and reduced all-cause mortality. HCV-infected patients with advanced fibrosis or cirrhosis should remain under HCC surveillance after SVR12, as residual cirrhosis continues to carry HCC risk even after viral cure. Ribavirin (RBV), once essential to interferon-based therapy, has a very limited role in the DAA era – it is added to SOF/VEL or Vosevi for decompensated cirrhosis in selected cases – because modern pan-genotypic regimens achieve high SVR (sustained virologic response) rates without it.5
The most clinically dangerous DAA interactions are with strong CYP3A4/P-gp inducers: rifampin, rifabutin, carbamazepine, phenytoin, phenobarbital, and St. John’s wort reduce DAA plasma concentrations to subtherapeutic levels and are absolute contraindications with protease inhibitor-containing regimens (GLE/PIB, Vosevi). Amiodarone combined with any sofosbuvir-containing regimen carries a risk of serious symptomatic bradycardia, including fatal cases – this combination is contraindicated unless no alternative exists and continuous cardiac monitoring is available. Statins interact with NS3/4A inhibitors via CYP3A4/OATP1B inhibition – rosuvastatin is contraindicated with GLE/PIB; atorvastatin dose capping is required. Always perform a drug interaction check before initiating any DAA regimen using a validated resource such as hep-druginteractions.org.
Hepatitis D virus (HDV) is a defective RNA (ribonucleic acid) virus that requires hepatitis B virus (HBV) surface antigen (HBsAg) for assembly and transmission, making HDV infection possible only in patients with concurrent or prior HBV infection. HDV superinfection of a chronic HBV carrier produces the most severe form of viral hepatitis, with accelerated progression to cirrhosis in 70–80% of patients within 5–10 years and substantially elevated risk of hepatocellular carcinoma. HDV was long a therapeutic orphan; bulevirtide, approved by the European Medicines Agency (EMA) in 2020 and under expanded use protocols elsewhere, represents the first specifically approved pharmacological agent targeting HDV.
HDV entry into hepatocytes requires interaction between the large HDV surface antigen and the sodium-taurocholate cotransporting polypeptide (NTCP) receptor on the hepatocyte basolateral membrane – the same receptor used by HBV for hepatocyte entry. Bulevirtide is a synthetic lipopeptide derived from the preS1 domain of the HBV large surface antigen that competitively blocks NTCP, preventing both HBV and HDV from entering hepatocytes. Because bulevirtide blocks new cell entry rather than intracellular replication, it does not directly reduce HDV RNA in already-infected cells; its virological effect requires time as infected cells turn over. In the phase 3 MYR301 (the pivotal bulevirtide registration trial) trial, bulevirtide 2 mg subcutaneously daily for 48 weeks achieved undetectable HDV RNA in 45% of patients and combined virological and biochemical response in approximately 48% of patients at week 48, compared with less than 5% in the delayed-treatment control group.8 A 10 mg daily dose showed numerically higher virological response but both doses are under continued evaluation. Bulevirtide is generally well tolerated; the most notable laboratory finding is dose-dependent elevation of conjugated bile acids in serum (reflecting NTCP blockade and reduced bile acid uptake), which is pharmacodynamic rather than hepatotoxic and does not require treatment discontinuation in most cases.
Pegylated interferon-alpha (PegIFN) has been the standard antiviral treatment for HDV for decades, acting via immune stimulation and direct antiviral interferon-stimulated gene induction. PegIFN-alpha-2a 180 mcg weekly for 48 weeks achieves undetectable HDV RNA in approximately 25–30% of patients at end of treatment, but virological relapse is common after treatment cessation, with durable off-therapy response (defined as undetectable HDV RNA 24 weeks post-treatment) achieved in approximately 20–25% of patients. The combination of bulevirtide plus PegIFN shows additive virological activity in early data, though the optimal combination strategy and treatment duration are subjects of ongoing trials. Because HDV requires HBsAg for assembly, suppression of HBV with NAs reduces the substrate available for HDV virion production and is recommended as background therapy; NA (nucleos(t)ide analogue) therapy alone does not meaningfully suppress HDV RNA but is indicated for concurrent HBV viral load management and liver protection.9
HDV infection is substantially underdiagnosed because anti-HDV antibody testing is not routinely included in standard HBV workup. All patients with HBsAg-positive chronic HBV and unexplained disease severity disproportionate to HBV DNA levels, or patients from HDV-endemic regions (Central Africa, Mongolia, Romania, Central Asia, Amazon basin), should be tested for anti-HDV. Confirmation of active HDV replication requires HDV RNA quantification by PCR, as anti-HDV IgG reflects exposure but does not distinguish active from resolved infection. Missing the diagnosis of HDV superinfection leads to undertreatment and missed opportunity for bulevirtide or PegIFN therapy, which cannot be applied if HDV is not recognized.
Acute liver failure (ALF) is defined by the development of coagulopathy (international normalized ratio (INR) ≥1.5) and encephalopathy in a patient without pre-existing liver disease, within 26 weeks of the onset of illness. It is a medical emergency with high short-term mortality without liver transplantation. In the United States, acetaminophen (APAP) overdose accounts for approximately 46% of ALF cases, followed by indeterminate etiology (~14%), idiosyncratic drug reactions (~11%), and viral hepatitis (~7%). Pharmacological management centers on the specific antidote N-acetylcysteine (NAC) for APAP-induced ALF, emerging evidence for NAC in non-APAP ALF, King’s College Criteria (KCC) for transplant listing, and intensive supportive care targeting complications.
The mechanism of APAP hepatotoxicity is well characterized. At therapeutic doses, APAP is conjugated by glucuronidation and sulfation; a small fraction undergoes CYP2E1 (cytochrome P450 2E1)-mediated oxidation to the reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI). NAPQI is rapidly detoxified by conjugation with hepatic glutathione (GSH). In overdose, glucuronidation and sulfation pathways saturate, shunting a larger fraction through CYP2E1 to NAPQI, which depletes hepatic GSH and then binds covalently to cellular proteins, causing mitochondrial dysfunction, oxidative stress, and hepatocyte necrosis. NAC replenishes GSH by providing cysteine, the rate-limiting substrate for GSH synthesis, thereby restoring the capacity to detoxify residual NAPQI.10 NAC is most effective when administered within 8–10 hours of APAP ingestion, when NAPQI is still being generated and GSH depletion is not yet maximal; efficacy diminishes but is not zero beyond this window. The standard intravenous NAC protocol is a three-bag regimen (150 mg/kg over 1 hour loading dose, then 50 mg/kg over 4 hours, then 100 mg/kg over 16 hours), totaling 300 mg/kg over 21 hours.
A landmark clinical trial demonstrated that intravenous NAC also improves transplant-free survival in non-acetaminophen ALF, albeit by a more modest magnitude than in APAP-induced disease.11 In the controlled trial, NAC-treated patients with non-APAP ALF had significantly higher transplant-free survival (40% vs. 27%), driven primarily by benefit in patients with early-grade (I–II) encephalopathy. Patients with advanced encephalopathy (grade III–IV) did not benefit significantly, likely reflecting irreversible injury at that stage. The mechanism in non-APAP ALF is thought to involve NAC’s broader antioxidant and cytoprotective properties beyond GSH repletion, including improved hepatic microcirculatory blood flow and mitochondrial function. NAC is now recommended in both APAP and non-APAP ALF in current guidelines, typically continued until INR improves or transplantation occurs.
The King’s College Criteria (KCC) are the most widely used prognostic tool for identifying ALF patients who are unlikely to survive without liver transplantation. The criteria differ by etiology. For APAP-induced ALF, the KCC identify high-risk patients by: arterial pH below 7.30 after resuscitation; or all three of serum creatinine above 3.4 mg/dL, prothrombin time above 100 seconds (INR >6.5), and grade III–IV encephalopathy. For non-APAP ALF, the criteria rely on: prothrombin time above 100 seconds (INR >6.5) alone; or any three of age below 10 or above 40 years, etiology (non-A non-B hepatitis or idiosyncratic drug reaction), jaundice-to-encephalopathy interval above 7 days, prothrombin time above 50 seconds (INR >3.5), and serum bilirubin above 17.5 mg/dL. Meeting KCC criteria should prompt urgent listing for emergency liver transplantation.12 The Model for End-Stage Liver Disease (MELD) score and dynamic scoring systems are complementary but KCC remain the most widely validated tool for acute transplant listing decisions.
Intensive care unit (ICU) supportive pharmacology in ALF addresses several simultaneous threats. Cerebral edema and intracranial hypertension are leading causes of death and are managed with osmotherapy (mannitol 0.5–1 g/kg intravenously for intracranial pressure (ICP) crises when ICP monitoring is in place) and hypertonic saline (targeting serum sodium of 145–155 mEq/L as prophylaxis against cerebral edema). Lactulose is commonly used for encephalopathy but evidence for benefit in ALF is limited and excessive administration can cause bowel distension impairing surgical access. Vasopressor support typically requires norepinephrine as first-line for the vasodilated, high-cardiac-output hemodynamic profile of ALF; vasopressin analogs may be added as second-line agents. Stress ulcer prophylaxis with proton pump inhibitors or H2 (histamine type-2) receptor blockers is standard. Broad-spectrum antimicrobial coverage for infections – which complicate approximately 80% of ALF cases – requires careful culture-directed selection because immunosuppression is already profound and fungal co-infections are common.13
APAP overdose confirmed or suspected: Initiate IV NAC immediately regardless of time since ingestion. Do not wait for acetaminophen levels if history is consistent. Use Rumack-Matthew nomogram for risk stratification at known ingestion times.
Non-APAP ALF: Initiate IV NAC for all comers with early-to-moderate encephalopathy (grade I–II). Benefit not established in grade III–IV but NAC is generally continued.
All ALF: Assess King’s College Criteria on presentation and repeat every 12–24 hours. Alert transplant center immediately if criteria met or trajectory is deteriorating. Transfer to a transplant-capable center should not be delayed for pharmacological stabilization alone.
Avoid: N-acetylcysteine oral loading in patients with encephalopathy (aspiration risk); sedatives and opioids that worsen encephalopathy; nephrotoxic agents; hepatotoxic drugs. Avoid lactulose in excess – target 2–3 soft stools/day, not catharsis.
Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359(23):2442–2455.
doi:10.1056/NEJMoa0802878Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology. 2009;49(5):1503–1514.
doi:10.1002/hep.22841Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599.
doi:10.1002/hep.29800Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351(12):1206–1217.
doi:10.1056/NEJMoa040431Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878–1887.
doi:10.1056/NEJMoa1214853Ghany MG, Morgan TR; AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology. 2020;71(2):686–721.
doi:10.1002/hep.31060Bourliere M, Gordon SC, Flamm SL, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med. 2017;376(22):2134–2146.
doi:10.1056/NEJMoa1613512Wedemeyer H, Aleman S, Brunetto MR, et al. A phase 3, randomized trial of bulevirtide in chronic hepatitis D. N Engl J Med. 2023;389(1):22–32.
doi:10.1056/NEJMoa2213429European Association for the Study of the Liver. EASL Clinical Practice Guidelines on hepatitis delta virus. J Hepatol. 2023;79(2):433–460.
doi:10.1016/j.jhep.2023.05.001Rumack BH, Bateman DN. Acetaminophen and acetylcysteine dose and duration: past, present and future. Clin Toxicol (Phila). 2012;50(2):91–98.
doi:10.3109/15563650.2012.659252Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 2009;137(3):856–864.
doi:10.1053/j.gastro.2009.06.006O’Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989;97(2):439–445.
doi:10.1016/0016-5085(89)90081-4Stravitz RT, Lee WM. Acute liver failure. Lancet. 2019;394(10201):869–881.
doi:10.1016/S0140-6736(19)31894-XZeuzem S, Foster GR, Wang S, et al. Glecaprevir–pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med. 2018;378(4):354–369.
doi:10.1056/NEJMoa1702417